Tavros Therapeutics, Inc., a precision oncology platform company, and OpenBench, Inc., a screening platform pioneering small molecule discovery partnerships, have entered into a collaboration to discover small molecule modulators of up to five oncology targets across an initial 18-month term. The agreement expands the companies’ original collaboration to pursue a first-in-class cancer target, announced in December 2021. OpenBench will receive an upfront payment for their services and payment ...